"We are … reviewing the Court's order. We look forward to continued engagement and successful collaboration with India on these issues," said Andrea Mead, a spokesperson for the U.S. Trade Representative's office.
The U.S.-India Business Council has noted that "over 40 countries including China, Russia and Taiwan have already granted a patent for Novartis' Glivec, and India now stands out as unique for not granting a patent to this incremental innovation."
The Office of the U.S. Trade Representative will have a chance to further comment on the Indian Supreme Court ruling, when it releases its annual report on intellectual property rights protection around the world. India is already on the report's "priority watch list" for countries with weak property rights protections.
U.S. trade office reviewing Supreme Court drug ruling | Reuters
WASHINGTON (Reuters) – The United States said on Tuesday it was considering its response to the Supreme Court ruling that U.S. drug manufacturers warn is the latest sign of a deteriorating environment…
Google+: View post on Google+